Trial results for a study investigating the value of glycated albumin (GA) in glycemic control for Chinese patients with Type 2 Diabetes were posted on ClinicalTrials.gov on 2025-12-04. The study found that GA-guided therapy significantly improved the achievement rate of HbA1c below 6.5%.
Background
Type 2 Diabetes Mellitus is a chronic condition characterized by high blood sugar levels. Glycated hemoglobin (HbA1c) is widely used as the primary marker for long-term glycemic control. However, for patients requiring adjustments to their hypoglycemic regimen, HbA1c may not be sensitive enough to reflect recent changes. Serum glycated albumin (GA) levels, which reflect average blood glucose over the preceding 2-3 weeks, offer a potentially more responsive marker for evaluating glycemic control. This study aimed to assess whether adjusting anti-diabetic regimens based on GA values could lead to improved glycemic control in newly diagnosed Type 2 Diabetes patients.
Trial design
This completed study, designated as Phase NA, enrolled 200 participants with Type 2 Diabetes Mellitus. The trial investigated whether knowledge of glycated albumin (GA) values and adjusting anti-diabetic regimens accordingly would improve glycemic control. Participants were randomized into two groups: one receiving GA-guided anti-diabetic therapy adjustment and another receiving treatment adjustment according to current guidelines.
Key results
The trial reported achievement rates for various HbA1c targets in both treatment arms:
- The Achievement Rate of HbA1c (<7%):
- For GA-guided anti-diabetic therapy adjustment, 63 participants and then 58 participants achieved this target.
- For the current guidelines to adjust treatment group, 65 participants and then 64 participants achieved this target.
- Chi-squared analysis yielded a p-value of 0.9917 (for an unspecified analysis) and 0.6555 (PPS analysis).
- The Achievement Rate of HbA1c (<6.5%):
- For GA-guided anti-diabetic therapy adjustment, 35 participants and then 32 participants achieved this target.
- For the current guidelines to adjust treatment group, 24 participants and then 23 participants achieved this target.
- Chi-squared analysis yielded a p-value of 0.0649 (FAS analysis) and 0.0342 (PPS analysis).
- The Achievement Rate of HbA1c (<6%):
- For GA-guided anti-diabetic therapy adjustment, 13 participants and then 13 participants achieved this target.
- For the current guidelines to adjust treatment group, 8 participants and then 7 participants achieved this target.
- Chi-squared analysis yielded a p-value of 0.2199 (FAS Analysis) and 0.0769 (PPS analysis).
What this means
The results suggest that utilizing glycated albumin (GA) values to guide anti-diabetic therapy adjustments may lead to improved glycemic control, particularly in achieving an HbA1c target below 6.5%. The difference for HbA1c <6.5% was statistically significant in the PPS analysis (p=0.0342), while the FAS analysis for the same target showed a trend towards improvement (p=0.0649). For other HbA1c targets (<7% and <6%), the differences were not statistically significant. This indicates that GA-guided therapy could be a valuable approach for more intensive glycemic management in Type 2 Diabetes patients, especially for those aiming for tighter control, though further research may be warranted to confirm these findings and explore broader applicability.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study NCT05227677, titled 'Value of Glycated Albumin in Intervention of Glycemic Control in Chinese Patients With Type 2 Diabetes', were posted on 2025-12-04 on clinicaltrials.gov.